

Primo “retreat” IRCCS Istituto Tumori “Giovanni Paolo II” di Bari

27-29 Maggio 2022

Centro di Spiritualità Madonna della Nova - Ostuni

Programma

Venerdì 27 Maggio 2022

18.00 Arrivo dei partecipanti	
18.30-19.30	Saluto di benvenuto Assessore alla Salute della Regione Puglia – dr. Rocco Palese Direttore del Dipartimento alla Salute della Regione Puglia – dr. Vito Montanaro Presidente CIV - On. Gero Grassi Direttore Generale - Avv. Alessandro Delle Donne Direttore Amministrativo - Dr.ssa Filomena Fortunato Direttore Sanitario - Dr. Pietro Milella Direttore Scientifico - Prof. Massimo Tommasino
19.30- 20.00	Breve presentazione del nuovo piano strategico della Direzione Scientifica – Prof. Massimo Tommasino
20:30–24:00	Cena ed incontro

Sabato 28 Maggio 2022

09.00- 09.15	Apertura Lavori	
Sessione 1	Linea 1: Dalla cancerogenesi alla progressione tumorale per una oncologia di precisione	
09:15–09:25	9:00-09.10 Biomarkers for Immunotherapy in SCLC	V. Longo
09:25–09.35	Circulating CD3+CD56+ cells as a biomarker for immunotherapy in SCLC – V. Longo	V. Longo
09.35-09.45	Hereditary small cell lung cancer	V. Longo
09.45-09.55	Searching for clinically relevant biomarkers and new nano drug delivery systems in precision oncology	A. Azzariti
09.55-10.05	Studio del microbiota e viroma dei polmoni nei pazienti affetti da patologia neoplastica polmonare	M. Garrisi
10.05-10.15	Advancing 3D-based models for preclinical validation of therapeutic hypothesis and the overcome of drug resistance	L. Porcelli
10.15-10.25	Association between mammographic density and body composition in the risk of developing breast cancer	A. Daniele
10.25-10.35	Unravelling the molecular roadmap to CEBPA-mutant driven leukaemogenesis	G. Volpe
10.35-10.45	Allelic frequency of BRAF V600E and NRAS mutations as predictive biomarkers in stage III and IV melanoma patients treated with target therapy and checkpoint inhibitors	M. Guida, S. Strippoli
10.45-11.10	Coffee break	



11.10-11.20	Body fluids viral and host biomarkers for head and neck cancer prevention/early diagnosis	L. Galati
11.20-11.30	Role of NDRG1 in invasive breast cancer and in the sub-group of TNBC: clinical impact and therapeutic implications	C. Saponaro
11.30-11.40	Downstream signaling of inflammasome pathway affects patients' outcome in the context of distinct molecular breast cancer subtypes	L. Schirosi
11.40-11.50	Non-coding RNA signatures in urinary extracellular vesicles as a non-invasive diagnostic biomarker for prostate cancer	G. De Palma
11.50-12.00	Human ovarian stem cells: biological aspects, functional properties and potential application for fertility preservation in oncology	G. De Palma, E. Silvestris
12.00-12.10	Metabolomic profile of patients with metastatic melanoma (MM) treated with immune checkpoint inhibitors –	M. Guida
13.00-15.00	Pranzo	
Sessione 2	Linea 2: La sperimentazioni cliniche nell'era della oncologia di precisione	
15.00-15.10	La comunicazione della diagnosi genetica nelle famiglie BRCA	S. Costanzo
15.10-15.20	Science Cafè: an exciting way to share data and experience in science	S. Ciavarella
15.20-15.40	Combining big data analysis and mathematics for dissecting tumor microenvironment in hematological malignancies: a new model of hypothesis-generation for prognostic/predictive purposes	S. Ciavarella
15.40-15.50	Development of a cellular predictive model for the evaluation of treatments in tumor cachexia associated with chemotherapy treatment	V. Lorusso
15.50-16.00	Endopredict as genomic test to aim treatment decision in early-stage breast cancer	V. Lorusso
16.00-16.10	Prospective assessment of Minimal Residual	M. Montrone



	Disease by ctDNA analysis in patients with locally advanced resectable or unresectable non-small cell lung cancer undergoing curative treatment: a pilot study	
16.10-16.30	Coffee break	
Sessione 3	Linea 3 Scienze Computazionali e Tecnologie di Intelligenza Artificiale: driver per una Oncologia Digitale	
16.30-16.40	Designing artificial intelligence-based support systems within the oncological field	R. Massafra
16.40-16.50	Artificial Intelligence Approaches to Predict the Lymph-Node Sentinel in Breast Cancer Patients	S. Bove
16.50-17.00	Artificial Intelligence Approaches to Investigate Breast Cancer Related Invasive Disease Events Occurrence in Patients Undergoing Adjuvant Chemotherapy	S. Bove
17.00-17.10	Early prediction of neoadjuvant chemotherapy response through a deep learning-based approach exploiting breast DCE-MRIs	M.C. Comes
17.10-17.20	Development of an artificial intelligence model to drive adjuvant treatment in patients with intermediate risk, HER2 negative hormone receptor positive breast cancer: radio-genomic analysis and prediction of the EndoPredict Recurrence Score Risk	A. Fanizzi
17.20-17.30	Prediction of radio-toxicity and HPV status in locally advanced oropharyngeal cancer patients	R. Massafra
17.30-17.40	Artificial intelligence-based approach to predict lymph node status and recurrence from whole slide images of primary melanoma	M.C. Comes
17.40-17.50	Development of a radiomic-based tool for the prediction of treatment outcomes and radiotherapy toxicity in patients with lung cancer	A. Fanizzi
17.50-18.00	Prediction of breast cancer histological outcome by radiomics and artificial intelligence analysis in Contrast-enhanced spectral mammography	D. Laforgia, R. Signorile



18.00-18.10	ARGO, Automatic Record Generator for Onco-hematology: a natural language processing tool to automatically generate eCRFs from real-life pathology reports	G. Zaccaria, S. Ciavarella
18.10-18.20	Artificial intelligence models for estimating progression-free survival and overall survival in locally advanced metastatic HR + / HER2-breast cancer patients treated with the combination of cyclin kinase inhibitors 4/6 and hormone therapy	To be defined
18.20-18.30	Colon cancer: a multi-layer approach from genomics to pathomics to support diagnosis and dissect biology	S. De Summa
18.30-18.40	Prognostic stratification in unresectable LA-NSCLC and assessment of response to chemo-radiotherapy: applications of artificial intelligence technologies	M. Montrone
18.40-18.50	Impact of concomitant medications on clinical outcomes in cancer patients treated with immune checkpoint inhibitors	A. Rizzo
19.00- 20.00	Presentazione Poster	
1	A Method Study Evaluating the Utility of circulating Tumour DNA to Detect BRCA1 and BRCA2 variants in Prostate cancer	S. Tommasi
2	Patient-derived organotypic tumor cultures of metastatic melanoma for personalised therapeutic screening (dr.ssa Roberta Di Fonte)	R. Di Fonte
3	Peritoneal lavage fluid from patients with colorectal cancer: a possible source of metastatization markers	S. Serrati'
4	Genomic profile of Merkel Cell Carcinoma patients	S. Tommasi
5	Anogenital lesions induced by different mucosal human papillomaviruses have different levels of PDZ protein na/H exchange regulatory factor-1	C. Saponaro



20:00–24:00	Cena	
Domenica 29 Maggio 2022		
Sessione 4	Linea 3 Scienze Computazionali e Tecnologie di Intelligenza Artificiale: driver per una Oncologia Digitale	
09.00-09.10	When the organizational model improve best practice. the case of central venous catheter (cva) management in cancer patients	G. Mastrandrea
09.10-09.20	Artificial intelligence models for the prediction of complications in patients undergoing rt after conservative surgery or mastectomy	S. Iacovelli
09.20-09.30	Artificial intelligence techniques and possible application for prognostic assesment and development of predictive models of therapeutical response in patients with unresectable pleural mesothelioma	A. Catino
09.30-09.40	Applicazioni della digital pathology nella oncologia di precisione	M. Sonnessa
Sessione 5	Linea 4: Nuovi modelli organizzativo-gestionali in oncologia	
09.40-09.50	A new score to assess the perioperative period of the cancer patient undergoing non-palliative elective surgery: a retrospective evaluation	G. Mastrandrea
09.50-10.00	Monitoring the activities of the multidisciplinary team of thoracic phatology in patients with locally advanced non-small cell lung cancer: evaluation of the performance of the multidisciplinary team and definition of the best diagnosctic and therapeutic path	M. Montrone
10.00-10.10	Risk of unemployment among chronic myeloproliferative disorders patients	P. Ditunno
10.10-10.45	Coffee break	
Sessione 6	OECI Molecular Tumor Board	
10.45-10.55	OECI Accreditation and Designation Programme	A. Lapietra
10.55-11.05	Molecular Tumor Board Istituzionale	S. Tommasi



Sessione 7

Fine ore 13.00

Considerazioni e Chiusura dei lavori